Core Viewpoint - ST New潮 is facing significant challenges, including the inability to disclose its 2024 financial report on time and the looming risk of delisting, primarily due to internal control issues and a complex ownership structure that has led to a lack of actual control over its assets [1][29]. Financial Performance - ST New潮 has reported impressive financial figures, including overseas oil and gas assets valued at over 30 billion, a net profit of 7.376 billion as of September 2024, and retained earnings of 6.947 billion [1]. - However, approximately 99% of these assets and profits are trapped in its U.S. subsidiaries, with the domestic parent company failing to distribute dividends for 15 years and accumulating significant debt [1]. Corporate Governance Issues - The company has been under scrutiny for its internal control deficiencies, leading to its designation as ST (Special Treatment) and increasing the risk of delisting [1][29]. - The lack of a real controlling shareholder and the ongoing governance disputes have resulted in a complex web of ownership and financial maneuvers that have left the company vulnerable [1][11]. Acquisition Interest - Despite its challenges, ST New潮 has attracted interest from major capital players, with significant bids for acquisition, including a recent 11.8 billion cash offer from Inner Mongolia's coal giant Yitai Group [4][18]. - The competition for ST New潮's assets highlights the perceived value of its overseas oil and gas holdings, despite the inherent risks associated with its governance and financial structure [4][23]. Historical Context - ST New潮 has a long history, originally established as a textile factory in 1985, and has undergone multiple transformations, ultimately becoming a "super shell" in the A-share market [5][6]. - The company has experienced numerous significant equity transfers and asset maneuvers, totaling over 15 major transactions involving more than 15 billion [9][11]. Regulatory Challenges - The complexity of ST New潮's asset control chain has raised concerns among regulators, particularly regarding the transparency and veracity of its overseas operations [24][32]. - The company's recent internal control audit revealed that only 18% of its overseas assets were subject to review, raising alarms about the reliability of its financial reporting [24][27]. Future Outlook - The potential acquisition of ST New潮 poses a high-risk gamble for interested parties, as the ability to effectively manage and repatriate its overseas assets remains uncertain [30][32]. - The ongoing governance issues and the intricate ownership structure could hinder any new owner's ability to realize the value of ST New潮's substantial overseas assets [30][32].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001256 证券简称：炜冈科技 公告编号：2025-026 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证季度报告中财务 信息的真实、准确、完整。 3、第一季度报告是否经审计 □是 R否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 其他符合非经常性损益定义的损益项目的具体情况 □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号— ...

Core Viewpoint - The company has disclosed its first-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented, with no significant omissions or misleading statements [2][10][20]. Financial Data Summary - The company reported a 36.66% decrease in cash and cash equivalents compared to the beginning of the period, primarily due to reduced sales collections and repayment of bank loans [4]. - Prepayments increased by 94.28%, attributed to higher advance payments for raw material purchases [4]. - Accounts payable decreased by 48.55%, mainly due to payments made for raw materials [4]. - Net cash flow from operating activities decreased by 105.36% year-on-year, resulting from a decline in revenue [5]. - Net cash flow from investing activities increased by 1.0988 million yuan year-on-year, due to the recovery of external investment funds [5]. - Net cash flow from financing activities increased by 62.43% year-on-year, primarily due to a reduction in bank loan repayments [5]. - Employee compensation payable decreased by 66.89% compared to the beginning of the period, due to the distribution of last year's performance bonuses [7]. - Tax payable decreased by 34.97%, mainly due to a reduction in value-added tax [7]. - Research and development expenses decreased by 38.34% year-on-year, attributed to reduced investment in R&D projects [7]. - Investment income decreased by 63.36% year-on-year, mainly due to a reduction in discount interest on notes [7]. Shareholder Information - The company has not reported any changes in the top ten shareholders or any significant shareholder lending activities [5]. Other Important Matters - The company is actively pursuing the recovery of external investment funds, with a total of 31.7482 million yuan owed by a partner, which has led to arbitration proceedings due to non-payment [6]. - A wholly-owned subsidiary has provided a guarantee for a financing loan of up to 5 million yuan from China Everbright Bank [7]. Board and Supervisory Meetings - The board of directors and the supervisory board have both approved the first-quarter report, confirming that the report complies with legal and regulatory requirements [12][20]. - The company has appointed a new securities affairs representative, Zhou Zexu, whose qualifications meet the necessary regulatory standards [24][26].

Core Viewpoint - The article discusses the financial and governance crisis faced by Clear Medical (01406.HK), a Hong Kong-listed ophthalmology service provider, following multiple trading suspensions and allegations of systematic fraud during its IPO process [1][2][9]. Group 1: Company Background and IPO - Clear Medical was considered a "star IPO" in 2022, raising HKD 218 million at an issue price of HKD 1.60 per share [2]. - The company claimed that its founders received a fixed salary of HKD 200,000 per month, which contributed significantly to its reported profits during the fiscal years 2019-2021 [2]. - However, it was revealed that the founders actually received performance-based variable compensation, with one founder's actual salary reaching HKD 12.61 million in the 2019 fiscal year, contradicting the IPO disclosures [2][3]. Group 2: Financial Performance Post-IPO - Following the termination of fixed salary contracts by the founders, Clear Medical's net profit plummeted to a loss of HKD 3.19 million in the 2023 fiscal year, down from a profit of HKD 13.49 million in 2022 [3]. - The company distributed HKD 148 million in dividends from 2019 to 2021, exceeding its total profits during that period by 40% [3]. Group 3: Allegations and Key Individuals - An anonymous email alleged that a key figure, Mok Tsan San, acted as an intermediary for "illegal IPO funds" and attempted to manipulate the new management team [4][5]. - Mok has a controversial history, having been involved in companies that faced significant stock price declines and eventual delistings [5]. - The article highlights ongoing concerns regarding the old management team, particularly regarding their influence and potential attempts to undermine the new management [7][8]. Group 4: Regulatory Actions and Market Implications - The Hong Kong Securities and Futures Commission is expected to investigate the allegations, which raises broader concerns about the integrity of the IPO process and corporate governance in the Hong Kong market [9]. - The article emphasizes the need for a shift towards transparent and responsible management to restore trust in the Hong Kong capital market [9].

岗位要求： 1、本科以上学历 2、对企业和上市公司感兴趣 3、有较强的职业精神 主要职责： 负责企业和上市公司调研、访谈、报告撰写等 工作地点： 北京西直门 五险一金，薪资面议 欢迎 发送简历至 youngcaijing@163.com 期待你的加入。 ■ YOUNG财经 招聘财经编辑数名 【YOUNG财经——关注商业伦理】 YOUNG财经从商业伦理视角关注商业世界，倡导帕累托最优的进化发展方式，支持市场公平和市场 效率，提倡第三方监督的力量。期待共赢而没有人受损的永续繁荣。关注绿色、社群和公司治理，倡 导包容、可持续发展理念。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600997 证券简称：开滦股份 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人彭余生、主管会计工作负责人张嘉颖及会计机构负责人（会计主管人员）林燕保证季度报告 中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三)主要会计数据、财务指标发生变动的情况、原因 ...

Core Viewpoint - Chengdu Yuntu Holdings Co., Ltd. is preparing for its 2024 annual shareholders' meeting, where several important proposals will be discussed, including changes to the board of directors and capital increase for its subsidiary [21][22][63]. Financial Data - The company has confirmed that its quarterly report is accurate and complete, with no need for restatement of previous financial data [2][3]. - The first quarter report has not been audited [6]. Board Meeting and Resolutions - The 31st meeting of the sixth board of directors was held on April 25, 2025, where several resolutions were passed, including the approval of the first quarter report and a capital increase for its subsidiary [10][11]. - The board has proposed changes to the company's operational scope and governance documents, which will be submitted for approval at the upcoming shareholders' meeting [12][13]. Shareholder Information - The company will hold its 2024 annual shareholders' meeting on May 6, 2025, where shareholders will vote on various proposals, including the election of new board members [21][23]. - The meeting will include a combination of on-site and online voting options for shareholders [25][26]. Capital Increase and Project Development - The company plans to increase the registered capital of its wholly-owned subsidiary, Guangxi Yuntu New Materials Co., Ltd., from 50 million yuan to 300 million yuan to support the Guangxi project [64][65]. - This capital increase is part of a broader investment cooperation agreement with local governments in Guangxi [64].

Core Points - The company, Henan Dayou Energy Co., Ltd., has announced its first quarter financial report for 2025, ensuring the accuracy and completeness of the information provided [3][6][7] - The company plans to absorb and merge its wholly-owned subsidiary, Aral YN Investment Co., Ltd., which will result in the transfer of all assets, liabilities, and rights to the parent company [16][18][20] - The company will provide an 80% joint liability guarantee for its subsidiary, Akesu Tahua Mining Co., Ltd., for a loan renewal of 150 million yuan [10][12][13] Financial Data - The financial statements for the first quarter of 2025 are unaudited and include key financial indicators [3][5] - The company has not yet executed new accounting standards or interpretations that would affect the financial statements for the year [5][6] Shareholder Information - The company will hold its 2024 annual general meeting on May 16, 2025, with a record date of May 9, 2025 [22][25] - The meeting will utilize a combination of on-site and online voting methods [25][30] Board Resolutions - The board of directors approved several resolutions, including the first quarter report, the guarantee for the subsidiary's loan, and the merger of the subsidiary [7][8][16] - The resolutions were passed unanimously with no dissenting votes [8][9]

【YOUNG财经——关注商业伦理】 YOUNG财经从商业伦理视角关注商业世界，倡导帕累托最优的进化发展方式，支持市场公平和市场 效率，提倡第三方监督的力量。期待共赢而没有人受损的永续繁荣。关注绿色、社群和公司治理，倡 导包容、可持续发展理念。 岗位要求： 1、本科以上学历 2、对企业和上市公司感兴趣 3、有较强的职业精神 主要职责： 负责企业和上市公司调研、访谈、报告撰写等 工作地点： 北京西直门 五险一金，薪资面议 欢迎 发送简历至 youngcaijing@163.com 期待你的加入。 ■ YOUNG财经 招聘财经编辑数名 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688056 证券简称：莱伯泰科 公告编号：2025-015 北京莱伯泰科仪器股份有限公司 第四届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）第四届董事会第十六次会议通知于2025年4月11日 以书面形式发出，并于2025年4月24日在公司会议室以现场与通讯相结合的方式召开。会议应出席董事7 人，实际出席董事7人。公司监事和高级管理人员列席了会议。 会议由董事长胡克先生召集并主持。会议的召开符合有关法律、行政法规、部门规章和《北京莱伯泰科 仪器股份有限公司章程》（以下简称"《公司章程》"）的规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于公司〈2024年年度报告〉及其摘要的议案》 经审议，董事会同意公司报出《2024年年度报告》及其摘要。公司董事会认为公司《2024年年度报告》 的编制和审议程序符合法律、法 ...